Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.09.02.748823

Retrospective Computational and Immunoinformatics Validation of Clinically Evaluated Necator americanus Protein Vaccine Candidates: Na-APR-1, Na-GST-1, and Na-ASP-2

Abstract

Hookworm disease, primarily caused by Necator americanus, affects about 472 million people worldwide and contributes substantially to global disease burden, yet no approved vaccine is currently available. The clinical failure of Na-ASP-2 protein due to IgE-mediated hypersensitivity highlights the need for safe, immunogenic hookworm vaccines and emphasizes the importance of rigorous pre-clinical safety screening. Using an integrated immunoinformatics approach, this work retrospectively evaluated the safety and immunogenicity of three clinical hookworm protein vaccine candidates: Na-APR-1, Na-GST-1, and Na-ASP-2. Toxigenicity and allergenicity predictions correctly identified Na-ASP-2 as toxigenic and allergenic, consistent with its documented clinical failure, while Na-APR-1 exhibited a favourable safety profile; Na-GST-1 showed inconsistent allergenicity signals warranting experimental validation. Comprehensive epitope prediction identified abundant CTL, HTL, B-cell, and cytokine-inducing epitopes across all candidates, with Na-APR-1 demonstrating the broadest epitope repertoire. HLA population coverage analysis indicated broad global applicability across endemic regions. Molecular docking with TLR4 revealed that all antigens interact with the receptor with binding energies more favourable than the positive control agonist, with Na-GST-1 and Na-APR-1 displaying the strongest predicted affinities. Normal mode analyses predicted stable antigen-TLR4 complex dynamics across all candidates. Immune simulations predicted robust, memory-driven humoral and cellular responses for Na-APR-1 and Na-ASP-2, while Na-GST-1 showed markedly attenuated simulated immunogenicity despite favourable structural and receptor-binding characteristics. These findings support continued clinical development of Na-APR-1, highlight unresolved immunogenic discordances for Na-GST-1 requiring experimental verification, and collectively provide a validated computational framework for advancing rational hookworm vaccine design.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Tangan, Y. A. S., Nchanji, G. T., Moyeh, M. N., Efeti, T. M., Lahngong, M. S., Nkineh, K. P., Ayuk, A. B., Engarimbi, J. E., Achungu, C. R., Shintouo, C. M., Berinyuy, D. M., Yaah, N. E., Yengo, B. N., Muyer, T. B., Gwei, K. Y., Tebo, B. T., Nyah, N. G., Ghogomu, S. M., Shey, R. A.. 2026-09-08. Retrospective Computational and Immunoinformatics Validation of Clinically Evaluated Necator americanus Protein Vaccine Candidates: Na-APR-1, Na-GST-1, and Na-ASP-2. https://doi.org/10.64898/2026.09.02.748823

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Ksp37 is a rapidly mobilized NK cell secretory protein that engages FGF2

A key feature of natural killer (NK) cells is their preloaded arsenal of effector molecules, allowing them to rapidly respond upon activation. In this study, we characterized a previously unexplored secretory protein, termed killer-specific secretory protein of 37 kDa (Ksp37), which is highly abundant in differentiated CD56dim NK cells. Ksp37 is rapidly secreted in a dose-dependent and JAK-1 dependent manner upon low levels of cytokine stimulation, making it a sensitive readout for NK cell activation. Following secretion, intracellular levels were rapidly replenished, preserving responsiveness to subsequent cytokine stimulation. We found that Ksp37 is stored in polarized intracellular compartments distinct from those containing canonical cytotoxic effector molecules, including granzyme B and perforin, which require stronger stimulation for release. Lastly, we identified Ksp37 as a novel binding partner of fibroblast growth factor 2 (FGF2). This opens new avenues of exploration for the role of NK cells in remodeling their extracellular environment by modulating the FGF2-FGFR1 axis, which plays a key role in tumor growth, angiogenesis and tissue repair.

immunology↗

ACE-engineered human iPSC-derived neutrophils enhance host defense against multidrug-resistant bacterial infections

Severe neutropenia predisposes patients to life-threatening infections, while donor-dependent granulocyte transfusions are limited by availability and variable cell quality. Here, we engineered human induced pluripotent stem cells (iPSCs) to constitutively or inducibly express angiotensin-converting enzyme (ACE) and differentiated them into functional ACE-engineered neutrophils (ACE-iNeu). ACE expression enhanced granulocytic maturation, reactive oxygen species generation, inflammatory cytokine production, and antimicrobial signaling. ACE-iNeu exhibited enhanced bactericidal activity against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. Following adoptive transfer into neutropenic mice, ACE-iNeu significantly reduced circulating and tissue bacterial burdens. Integrated metabolomic and transcriptomic analyses revealed ACE-associated alterations in adenine nucleotide abundance and developmental and inflammatory pathways. Together, these findings establish ACE engineering as a strategy to enhance the production and antimicrobial function of human iPSC-derived neutrophils and support further preclinical development of engineered granulocyte therapies for severe drug-resistant infections.

immunology↗

Tetravalent dengue mRNA vaccination orchestrates balanced four-serotype immunity with durable memory and protection in mice.

An effective dengue vaccine must establish durable immunity across four dengue virus (DENV) serotypes, evade antibody-dependent enhancement (ADE), and overcome immune imprinting from prior exposure. Here, we developed TetprM-E mRNA-LNP, a tetravalent vaccine comprising LNP-formulated nucleoside-modified mRNAs encoding DENV1-4 precursor membrane-envelope (prM-E) antigens, and evaluated its immunogenicity, durability, protection and breath across serotype-specific immune backgrounds. Three immunization strategies elicited neutralizing titers greater than 1:1500 against each serotype. Passive transfer of immune sera conferred 100% survival and reduced viremia after lethal DENV2 challenge in immunocompromised mice. Vaccination induced DENV envelope (env)-specific CD8+T cells and CD4-dependent germinal-center responses. DENV env-binding antibodies persisted for 34 weeks alongside DENV env-specific memory B cells. Vaccine-elicited sera showed no measurable in vitro ADE. Although monovalent priming initially biased antibody responses, TetprM-E mRNA-LNP vaccination broadened neutralization across DENV1-4 regardless of priming serotype. Together, TetprM-E mRNA-LNP elicits broad, durable, and protective immunity despite serologic constraints from pre-existing immunity.

immunology↗